In response to our recent narrative review [1], Carmona-Bayonas et al. question whether the Clinical Index of Stable Febrile Neutropenia (CISNE) or Multinational Association of Supportive Care in Cancer (MASCC) score is really the weakest in febrile neutropenia [2]. The basic premise is simple and broadly accepted – outpatient of patients with low risk febrile neutropenia is safe and effective [3,4]. The question of how to identify these patients and develop safe pathways for their care in the myriad of settings that deliver emergency oncology care is significantly more challenging [5].
